{"id":4363,"date":"2023-05-11T14:52:00","date_gmt":"2023-05-11T14:52:00","guid":{"rendered":"http:\/\/www.enyopharma.com\/fr\/?page_id=4363"},"modified":"2024-01-03T09:58:59","modified_gmt":"2024-01-03T09:58:59","slug":"autres-programmes","status":"publish","type":"page","link":"https:\/\/www.enyopharma.com\/fr\/science\/autres-programmes\/","title":{"rendered":"Autres programmes"},"content":{"rendered":"<h2>Vonafexor dans l\u2019H\u00e9patique B et l\u2019H\u00e9patique D<\/h2>\n<p><img decoding=\"async\" class=\"img-thumbnail wp-image-116 size-thumbnail alignleft\" src=\"\/wp-content\/uploads\/2023\/05\/liver_small.png\" alt=\"Liver\" width=\"150\"\/><\/p>\n<p>En plus de son effet fibrolytique et anti-inflammatoire consid\u00e9rable, Vonafexor pr\u00e9sente des propri\u00e9t\u00e9s antivirales contre le virus de l&#8217;h\u00e9patite B (VHB) et le virus de l&#8217;h\u00e9patite D (VHD).<\/p>\n<p>ENYO Pharma a d\u00e9j\u00e0 men\u00e9 5 \u00e9tudes cliniques (3 Phases 1 et 2 Phases 2) avec Vonafexor pour l\u2019H\u00e9patite B. <a href=\"https:\/\/www.enyopharma.com\/science\/clinical-trials\/\" target=\"_blank\"> Cliquez ici pour plus d\u2019informations.<\/a> <\/li>\n<ul>\n<li><b>Radreau et al. (2016)<\/b>: Reciprocal regulation of Farnesoid X Receptor a activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes. FASEB J. <a href=\"https:\/\/faseb.onlinelibrary.wiley.com\/doi\/abs\/10.1096\/fj.201500134\" target=\"_blank\">Radreau et al. (2016)<\/a><\/li>\n<li><b>Curtil et al. (2014)<\/b>: The metabolic sensors FXR, PGC-1, and SIRT1 cooperatively regulate hepatitis B virus transcription. FASEB J. <a href=\"https:\/\/faseb.onlinelibrary.wiley.com\/doi\/abs\/10.1096\/fj.13-236372\" target=\"_blank\">Curtil et al. (2014)<\/a><\/li>\n<li><b>Rami\u00e8re et al (2008)<\/b>: The metabolic sensors FXR, PGC-1, and SIRT1 cooperatively regulate hepatitis B virus transcription. FASEB J. <a href=\"https:\/\/faseb.onlinelibrary.wiley.com\/doi\/abs\/10.1096\/fj.13-236372\" target=\"_blank\">Rami\u00e8re et al (2008)<\/a><\/li>\n<\/ul>\n<p>L\u2019H\u00e9patite D est \u00e9galement abord\u00e9e par ENYO Pharma dans des \u00e9tudes pr\u00e9cliniques utilisant Vonafexor.<\/p>\n<h2>Drug discovery platform<\/h2>\n<p><img decoding=\"async\" class=\"img-thumbnail wp-image-116 size-thumbnail alignleft\" src=\"\/wp-content\/uploads\/2023\/05\/Viruses_website_small.png\" alt=\"Viruses\" width=\"150\"\/><\/p>\n<p>\u00ab Il existe une \u00e9norme mine d\u2019or inexploit\u00e9e de cibles \u00e0 d\u00e9couvrir\u2026 \u00bb Jacky Vonderscher, PDG et co-fondateur d\u2019ENYO Pharma.<\/p>\n<p>Notre histoire a commenc\u00e9 en 2014 lorsque des experts en interactions virus-prot\u00e9ines h\u00f4tes du Centre de recherche en infectiologie (Inserm) de Lyon, en France, et des dirigeants de l&#8217;industrie pharmaceutique sp\u00e9cialis\u00e9s dans le d\u00e9veloppement de m\u00e9dicaments ont d\u00e9velopp\u00e9 une plateforme unique de d\u00e9couverte de m\u00e9dicaments bas\u00e9e sur le biomim\u00e9tisme inspir\u00e9 des virus.  <\/p>\n<h2>EYP002<\/h2>\n<p><img decoding=\"async\" class=\"img-thumbnail wp-image-116 size-thumbnail alignleft\" src=\"\/wp-content\/uploads\/2023\/05\/002_struct.jpg\" alt=\"EYP002\" width=\"150\"\/><\/p>\n<p>EYP002 est une nouvelle s\u00e9rie de compos\u00e9s chimiques de premi\u00e8re classe en cours d&#8217;optimisation, initialement d\u00e9velopp\u00e9s pour inhiber la r\u00e9plication de la grippe comme test ph\u00e9notypique. Les mol\u00e9cules modulent l&#8217;activit\u00e9 d&#8217;une petite famille de prot\u00e9ines mitochondriales, les prot\u00e9ines NEET cod\u00e9es par trois g\u00e8nes CISD.<\/p>\n","protected":false},"excerpt":{"rendered":"<h2>Vonafexor dans l\u2019H\u00e9patique B et l\u2019H\u00e9patique D<\/h2>\n<p><img decoding=\"async\" class=\"img-thumbnail wp-image-116 size-thumbnail alignleft\" src=\"\/wp-content\/uploads\/2023\/05\/liver_small.png\" alt=\"Liver\" width=\"150\"\/><\/p>\n<p>En plus de son effet fibrolytique et anti-inflammatoire consid\u00e9rable, Vonafexor pr\u00e9sente des propri\u00e9t\u00e9s antivirales contre le virus de l&#8217;h\u00e9patite B (VHB) et le virus de l&#8217;h\u00e9patite D (VHD).<\/p>\n<p>ENYO Pharma a d\u00e9j\u00e0 men\u00e9 5 \u00e9tudes cliniques (3 Phases 1 et 2 Phases 2) avec Vonafexor pour l\u2019H\u00e9patite B. <a href=\"https:\/\/www.enyopharma.com\/science\/clinical-trials\/\" target=\"_blank\"> Cliquez ici pour plus d\u2019informations.<\/a> <\/p>\n<ul>\n<li><b>Radreau et al.<\/b><\/li>\n<\/ul>\n<p><a class=\"read-more\" href=\"https:\/\/www.enyopharma.com\/fr\/science\/autres-programmes\/\">Lire la suite&nbsp;&raquo;<\/a><\/p>\n","protected":false},"author":2,"featured_media":1014,"parent":4320,"menu_order":5,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-4363","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"jetpack_sharing_enabled":true,"rttpg_featured_image_url":{"full":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2016\/03\/pipeline.jpg?fit=2000%2C750&ssl=1",2000,750,false],"landscape":["https:\/\/www.enyopharma.com\/wp-content\/uploads\/2016\/03\/pipeline.jpg",2000,750,false],"portraits":["https:\/\/www.enyopharma.com\/wp-content\/uploads\/2016\/03\/pipeline.jpg",2000,750,false],"thumbnail":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2016\/03\/pipeline.jpg?resize=150%2C150&ssl=1",150,150,true],"medium":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2016\/03\/pipeline.jpg?fit=300%2C113&ssl=1",300,113,true],"large":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2016\/03\/pipeline.jpg?fit=1024%2C384&ssl=1",1024,384,true],"1536x1536":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2016\/03\/pipeline.jpg?fit=1536%2C576&ssl=1",1536,576,true],"2048x2048":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2016\/03\/pipeline.jpg?fit=2000%2C750&ssl=1",2000,750,true],"large_home":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2016\/03\/pipeline.jpg?fit=1400%2C525&ssl=1",1400,525,true]},"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":null,"rttpg_excerpt":"Vonafexor dans l\u2019H\u00e9patique B et l\u2019H\u00e9patique D En plus de son effet fibrolytique et anti-inflammatoire consid\u00e9rable, Vonafexor pr\u00e9sente des propri\u00e9t\u00e9s antivirales contre le virus de l&#8217;h\u00e9patite B (VHB) et le virus de l&#8217;h\u00e9patite D (VHD). ENYO Pharma a d\u00e9j\u00e0 men\u00e9 5 \u00e9tudes cliniques (3 Phases 1 et 2 Phases 2) avec Vonafexor pour l\u2019H\u00e9patite B.&hellip;","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/pages\/4363","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=4363"}],"version-history":[{"count":4,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/pages\/4363\/revisions"}],"predecessor-version":[{"id":4728,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/pages\/4363\/revisions\/4728"}],"up":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/pages\/4320"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media\/1014"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=4363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}